The Antimalarial Drug Portfolio and Research Pipeline
作者： Wilbur K. Milhous , Piero L. Olliaro
DOI: 10.1007/978-1-59259-111-4_12
关键词: Pharmacology 、 Drug discovery 、 Risk analysis (engineering) 、 Malaria 、 Drug 、 Pipeline (software) 、 Uncomplicated malaria 、 Portfolio 、 Business 、 Case management 、 Drug pipeline
摘要: Drugs are the mainstay of malaria case management and prevention this situation is unlikely to change in foreseeable future. This chapter intends give following: A brief overview antimalarial drug pipeline, ranging from promising lead compounds current use that still undergoing research. A review 7 specific drugs or classes. A discussion implications discovery development view needs treatment prevention. The broad research agenda should, principle, investigate both opportunities leading next generation (unrelated existing ones, thus undamaged cross-resistance) how we have already developed can be protected resistance.
springer.com
sci-hub.st 参考文章(40)
S. Looareesuwan, P. Wilairatana, P. Olliaro, W. Molunto, M. Andrial, K. Chalermrut, A comparative clinical trial of sequential treatments of severe malaria with artesunate suppository followed by mefloquine in Thailand. American Journal of Tropical Medicine and Hygiene. ,vol. 57, pp. 348- 353 ,(1997) , 10.4269/AJTMH.1997.57.348
P A Phillips-Howard, A Björkman, Adverse reactions to sulfa drugs: implications for malaria chemotherapy. Bulletin of The World Health Organization. ,vol. 69, pp. 297- 304 ,(1991)
M. van Vugt, A. Brockman, B. Gemperli, C. Luxemburger, I. Gathmann, C. Royce, Thra Slight, S. Looareesuwan, N. J. White, F. Nosten, Randomized Comparison of Artemether-Benflumetol and Artesunate-Mefloquine in Treatment of MultidrugResistant Falciparum Malaria Antimicrobial Agents and Chemotherapy. ,vol. 42, pp. 135- 139 ,(1998) , 10.1128/AAC.42.1.135
Ai Jeng Lin, Daniel L Klayman, Wilbur K Milhous, None, Antimalarial activity of new water-soluble dihydroartemisinin derivatives. Journal of Medicinal Chemistry. ,vol. 30, pp. 2147- 2150 ,(1987) , 10.1021/JM00394A037
P Ringwald, J Bickii, P Ringwald, L Basco, L Basco, Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa The Lancet. ,vol. 347, pp. 24- 28 ,(1996) , 10.1016/S0140-6736(96)91558-5
V. Navaratnam, S. M. Mansor, M. N. Mordi, A. Akbar, M. N. Abdullah, Comparative pharmacokinetic study of oral and rectal formulations of artesunic acid in healthy volunteers. European Journal of Clinical Pharmacology. ,vol. 54, pp. 411- 414 ,(1998) , 10.1007/S002280050484
N.J. White, Preventing antimalarial drug resistance through combinations Drug Resistance Updates. ,vol. 1, pp. 3- 9 ,(1998) , 10.1016/S1368-7646(98)80208-2
Peter Winstanley, William Watkins, David Muhia, Simon Szwandt, Evans Amukoye, Kevin Marsh, Chlorproguanil/dapsone for uncomplicated Plasmodium falciparum malaria in young children : pharmacokinetics and therapeutic range Transactions of The Royal Society of Tropical Medicine and Hygiene. ,vol. 91, pp. 322- 327 ,(1997) , 10.1016/S0035-9203(97)90093-6
S. Fu, S.-H. Xiao, Pyronaridine: A new antimalarial drug Parasitology Today. ,vol. 7, pp. 310- 313 ,(1991) , 10.1016/0169-4758(91)90267-R
Jill Curtis, M. T. Duraisingh, D. C. Warhurst, In Vivo Selection for a Specific Genotype of Dihydropteroate Synthetase of Plasmodium falciparum by Pyrimethamine-Sulfadoxine but Not Chlorproguanil-Dapsone Treatment The Journal of Infectious Diseases. ,vol. 177, pp. 1429- 1433 ,(1998) , 10.1086/517831